CLDX Jan 2023 70.000 call
| Previous Close | 4.0000 |
| Open | 4.0000 |
| Bid | 0.5500 |
| Ask | 3.6000 |
| Strike | 70.00 |
| Expire Date | 2023-01-20 |
| Day's Range | 4.0000 - 4.0000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
- Zacks
Celldex (CLDX) Initiates Phase II Chronic Skin Disorder Study
Celldex (CLDX) initiates dosing in a mid-stage study designed to evaluate its antibody candidate, barzolvolimab, for treating patients with chronic spontaneous urticaria.
- GlobeNewswire
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
HAMPTON, N.J., June 21, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 2 clinical study of barzolvolimab for the treatment of chronic spontaneous urticaria (CSU). Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. CSU is characterized by the occurrence of hives or wheals for 6 weeks or longer without i
- Simply Wall St.
We're Hopeful That Celldex Therapeutics (NASDAQ:CLDX) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
